Table 4 Meta-analysis of MTHFR A1298C polymorphism to ASD risk under the five genetic models
Genetic Models | Fixed/ Random effect OR(95%CI) | Heterogeneity P | I2(%) | Publication Bias P of Egger’s/Begg test |
|---|---|---|---|---|
Allele Contrast (C vs A) | 1.17 (0.91–1.50)b | 0.000 | 81.7 | 0.210/0.010 |
Mandatory fortification with folate | ||||
Yes | 0.91 (0.81–1.03)a | 0.153 | 40.3 | 0.086/0.098 |
No | 1.84 (1.08–3.14)b* | 0.002 | 86.0 | 0.086/0.095 |
Population | ||||
Asian | 1.31 (0.81–2.14)b | 0.002 | 84.4 | 0.296/0.380 |
Caucasian | 1.11 (0.82–1.49)b | 0.000 | 80.9 | 0.548/0.045 |
Sample source | ||||
Hospital-based | 1.45 (0.88–2.39)b | 0.000 | 89.5 | 0.221/0.021 |
Population-based | 0.96 (0.84–1.10)a | 0.074 | 53.0 | 0.204/0.462 |
HWE | ||||
Yes | 1.13 (0.84–1.52)b | 0.000 | 80.9 | 0.368/0.043 |
No | 1.25 (0.73–2.15)b | 0.000 | 87.2 | 0.282/0.296 |
Heterozygote (AC vs AA) | 1.11 (0.82–1.50)b | 0.000 | 73.5 | 0.001/0.049 |
Mandatory fortification with folate | ||||
Yes | 0.87 (0.74–1.02)a | 0.302 | 17.6 | 0.382/0.462 |
No | 2.23 (0.98–5.09)b | 0.000 | 82.7 | 0.026/0.086 |
Population | ||||
Asian | 1.29 (0.68–2.44)b | 0.015 | 76.3 | 0.532/1.000 |
Caucasian | 1.04 (0.72–1.50)b | 0.001 | 74.7 | 0.002/0.230 |
Sample source | ||||
Hospital-based | 1.11 (0.71–1.74)b | 0.004 | 74.0 | 0.090/0.462 |
Population-based | 1.15 (0.72–1.86)b | 0.001 | 78.4 | 0.009/0.221 |
HWE | ||||
Yes | 1.04 (0.73–1.50)b | 0.001 | 74.6 | 0.001/0.133 |
No | 1.28 (0.66–2.47)b | 0.013 | 76.9 | 0.578/1.000 |
Homozygote (CC vs AA) | 1.31 (0.82–2.09)b | 0.000 | 72.0 | 0.025/0.152 |
Mandatory fortification with folate | ||||
Yes | 0.89 (0.67–1.18)a | 0.260 | 24.2 | 0.139/0.462 |
No | 2.98 (1.17–7.58)b | 0.002 | 75.8 | 0.143/0.221 |
Population | ||||
Asian | 1.78 (0.88–3.62)b | 0.041 | 68.8 | 0.811/1.000 |
Caucasian | 1.11 (0.62–2.01)b | 0.002 | 70.5 | 0.073/0.368 |
Sample source | ||||
Hospital-based | 1.87 (0.74–4.77)b | 0.000 | 83.6 | 0.044/0.462 |
Population-based | 1.02 (0.76–1.34)a | 0.208 | 32.0 | 0.066/1.000 |
HWE | ||||
Yes | 1.27 (0.68–2.35)b | 0.001 | 72.5 | 0.072/0.230 |
No | 1.45 (0.65–3.24)b | 0.014 | 76.7 | 0.966/1.000 |
Dominant (CC + AC vs AA) | 1.19 (0.87–1.64)b | 0.002 | 79.6 | 0.000/0.049 |
Mandatory fortification with folate | ||||
Yes | 0.87 (0.74–1.02)a | 0.205 | 32.5 | 0.198/0.221 |
No | 2.45 (1.16–5.15)b* | 0.000 | 84.5 | 0.005/0.086 |
Population | ||||
Asian | 1.38 (0.89–2.14)b | 0.054 | 65.8 | 0.291/1.000 |
Caucasian | 1.13 (0.75–1.72)b | 0.000 | 82.0 | 0.001/0.230 |
Sample source | ||||
Hospital-based | 1.43 (0.81–2.50)b | 0.000 | 86.6 | 0.019/0.462 |
Population-based | 1.03 (0.71–1.49)b | 0.011 | 69.2 | 0.014/0.221 |
HWE | ||||
Yes | 1.14 (0.76–1.73)b | 0.000 | 81.9 | 0.001/0.230 |
No | 1.34 (0.80–2.23)b | 0.023 | 73.4 | 0.306/1.000 |
Recessive (CC vs AC + AA) | 1.17 (0.76–1.78)b | 0.001 | 69.4 | 0.081/0.152 |
Mandatory fortification with folate | ||||
Yes | 0.94 (0.72–1.24)a | 0.363 | 7.7 | 0.192/0.462 |
No | 1.93 (0.70–1.25)b | 0.000 | 82.6 | 0.240/0.806 |
Population | ||||
Asian | 1.52 (0.54–4.33)b | 0.000 | 87.3 | 0.546/1.000 |
Caucasian | 0.99 (0.64–1.55)b | 0.486 | 52.8 | 0.174/0.368 |
Sample source | ||||
Hospital-based | 1.74 (0.76–3.99)b | 0.000 | 80.3 | 0.063/0.462 |
Population-based | 0.90 (0.69–1.19) a | 0.235 | 27.9 | 0.710/1.000 |
HWE | ||||
Yes | 1.12 (0.69–1.80)b | 0.025 | 58.5 | 0.163/0.368 |
No | 1.24 (0.46–3.36)b | 0.001 | 86.6 | 0.676/1.000 |